Mariam T. Nawas, MD, specializes in hematopoietic cell transplantation (HCT) and cellular therapies for adults suffering from hematologic malignancies. She also cares for patients with myeloid malignancies including acute myeloid leukemia, myelodysplastic syndrome, myeloproliferative neoplasms and clonal cytopenias. Her research interests lie in better understanding and reducing HCT and cell therapy-related toxicities and symptom burden, particularly in older adults. Dr. Nawas is the Director for Quality and Data Management and the Associate Clinical Director of the Jonas Center for Cellular Therapy. She also directs Transplant Optimization Program at the University of Chicago, a geriatric-assessment guided multidisciplinary clinic dedicated to evaluation and optimization of older adults undergoing HCT and cell therapy.
Hematologic complications in patients exposed to poly- ADP ribose polymerase inhibitors.
Hematologic complications in patients exposed to poly- ADP ribose polymerase inhibitors. Haematologica. 2026 Jul 01; 111(7):2451-2456.
PMID: 41609051
Outcomes of patients with relapsed/refractory acute leukaemia treated with revumenib with a focus on post-revumenib therapies.
Outcomes of patients with relapsed/refractory acute leukaemia treated with revumenib with a focus on post-revumenib therapies. Br J Haematol. 2026 Jan; 208(1):343-347.
PMID: 41139955
Factors associated with survival after allogeneic transplantation for myeloid neoplasms harboring TP53 mutations.
Factors associated with survival after allogeneic transplantation for myeloid neoplasms harboring TP53 mutations. Blood Adv. 2025 Jul 22; 9(14):3395-3407.
PMID: 40085959
Outcomes for Patients With Myeloid Neoplasms Treated With Chemotherapy Plus Venetoclax After Prior Venetoclax Therapy.
Outcomes for Patients With Myeloid Neoplasms Treated With Chemotherapy Plus Venetoclax After Prior Venetoclax Therapy. EJHaem. 2025 Jun; 6(3):e70078.
PMID: 40521395
US Geriatric Assessment Practices for Older Adults Undergoing Hematopoietic Cell Transplantation or Chimeric Antigen Receptor T Cell Therapy: An American Society for Transplantation and Cellular Therapy Physician Survey from the Aging Special Interest Group and Committee on Practice Guidelines.
US Geriatric Assessment Practices for Older Adults Undergoing Hematopoietic Cell Transplantation or Chimeric Antigen Receptor T Cell Therapy: An American Society for Transplantation and Cellular Therapy Physician Survey from the Aging Special Interest Group and Committee on Practice Guidelines. Transplant Cell Ther. 2025 May; 31(5):285-296.
PMID: 39961473
Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia.
Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia. Bone Marrow Transplant. 2025 Feb; 60(2):135-143.
PMID: 39537780
Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation.
Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation. Haematologica. 2024 Nov 01; 109(11):3739-3744.
PMID: 38618681
Optimization of older adults by a geriatric assessment-guided multidisciplinary clinic before CAR T-cell therapy.
Optimization of older adults by a geriatric assessment-guided multidisciplinary clinic before CAR T-cell therapy. Blood Adv. 2024 07 23; 8(14):3785-3797.
PMID: 38810262
Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms.
Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms. Blood Cancer J. 2024 06 18; 14(1):99.
PMID: 38890297
FLT3 inhibitor maintenance after allogeneic stem cell transplantation in FLT3-mutated acute myeloid leukemia (AML) patients.
FLT3 inhibitor maintenance after allogeneic stem cell transplantation in FLT3-mutated acute myeloid leukemia (AML) patients. Ann Transl Med. 2024 Jun 10; 12(3):49.
PMID: 38911560